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BACKGROUND: Low-dose computed tomography (LDCT) lung screening has been associated with a 20% reduction in lung cancer
mortality. A major barrier to the adoption of lung screening is the potential negative psychological impact of a false-positive (FP)
screen, occurring in 20% to 50% of those screened. The objective of this study was to assess the impact of abnormal findings on
health-related quality of life (HRQoL) and anxiety in the American College of Radiology (ACRIN)/National Lung Screening Trial
(NLST). METHODS: The NLST was a randomized screening trial comparing LDCT with chest X-ray screening (CXR). This study was
part of the original protocol. A total of 2812 participants at 16 of 23 ACRIN sites who had baseline HRQoL assessments were asked to
complete the Short Form-36 and the State Trait Anxiety Inventory (form Y-1) questionnaires to assess short-term (1 month) and long-
term (6 months) effects of screening. FP were lung cancer–free at 1 year, and true-positives (TP) were not. RESULTS: Of the total par-
ticipants, 1024 (36.4%) participants were FP, 63 (2.2%) were TP, 344 (12.2%) had significant incidental findings (SIFs), and 1381
(49.1%) had negative screens. Participants had been randomized to LDCT (n51947) and CXR (n5865). Short-term and long-term
HRQoL and state anxiety did not differ across participants with FP, SIF, or negative screens. Short-term and long-term HRQoL were
lower and anxiety was higher for TP participants compared to participants with FP, SIF, and negative screens. CONCLUSIONS: In a
large multicenter lung screening trial, participants receiving a false-positive or SIF screen result experienced no significant difference
in HRQoL or state anxiety at 1 or at 6 months after screening relative to those receiving a negative result. Cancer 2014;120:3401-9. V C
2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article
under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: quality of life, anxiety, lung cancer, screening, clinical trials.
INTRODUCTION
Lung cancer is the leading cause of cancer death in the United States.
1 Based on reduced lung cancer mortality in the low-
dose computed tomography (LDCT) arm of the National Lung Screening Trial (NLST),
2 the United States Preventive
Services Task Force released a grade B recommendation for provision of annual LDCT lung screening to adults 55 to 80
years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.
3 Several profes-
sional organizations have issued similar guidelines.
4 One of the barriers to the widespread adoption of LDCT lung screen-
ing is the current lack of knowledge regarding the potential adverse psychological impact of a false-positive screen, and the
large number of participants who will screen false-positive (20%-50%),
2,5-8 but who do not have lung cancer. Because
lungbiopsycarriesahighdegreeofrisktothepatient,currentguidelinesformanagementofLDCT-detectedlungnodules
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Original Articlerecommend serial monitoring for many patients with a
positive screening examination.
9,10 These patients may
endure an extended period of uncertainty regarding their
lung cancerstatus.
This extended monitoring is in direct contrast to the
experience of most patients screened for breast, colon, or
cervical cancer who receive their final diagnoses fairly rap-
idly following a biopsy of the suspicious lesion. Even so,
false positive breast cancer screens have been associated
with reduced health-related quality of life (HRQoL) and
increased anxiety.
11 For lung cancer screening, informa-
tion is limited to smaller studies and has been inconclu-
sive.
12,13 If receiving a positive screen result has short-
term (1 month) or long-term (6 months) impact on par-
ticipant quality of life and/or anxiety, physicians may be
less likely to refer high-risk individuals for LDCT screen-
ing,
5and patientsmay be less likely to adhereto an annual
screeningprotocol.
In addition,CT lung screeninghas a high rate of sig-
nificant incidental findings (SIFs), such as abdominal aor-
tic aneurysms and renal cysts (6%-14%). These findings
are unrelated to lung cancer,
2,14 but are often of sufficient
concern to warrant additional diagnostic evaluation. As
lungscreeningdiffusesintothecommunitywithlessexpe-
rienced radiologists evaluating screening images, the pro-
portionof screenswithdiagnosedSIFsmaygrow.
Given the high rate of false positive screens, the
large number of SIFs visualized with LDCT screening,
the inconsistent information available on the effect of
a false positive screen, and the lack of information on
the impact of SIF results, we planned to study the
impact of false positive and SIF screens on short-term
(1 month) and long-term (6 months) HRQoL and
anxiety in the NLST. The NLST is the largest trial of
lung CT screening conducted to date. We report on
the association between screen results (false-positive,
true-positive, SIF, and negative) and screening arm
(LDCT, CXR) and global HRQoL and state anxiety
in NLST participants.
MATERIALS AND METHODS
This HRQoL study was approved by the Institutional
Review Boards at each of the participating sites and at
Brown University. All participants gave informed consent
atthe siteof recruitment.
Study Population
TheNLSTwasamulti-institutionaltrialof53,452partic-
ipants designed to compare the ability of LDCT and
CXR imaging to reduce lung cancer mortality.
Participants received three screening examinations at one
year intervals: a baseline (T0) and 2 incidence screens (T1
and T2). Screening began in August of 2002. Follow-up
was concluded in December of 2009. Details on the
NLST study design have been published elsewhere.
15 The
NLST was a collaboration between the American College
of Radiology Imaging Network (ACRIN) and the
National Cancer Institute Division of Cancer Prevention
Lung Screening Study. ACRIN enrolled 18,840 partici-
pants at 23 sites. During the informed consent process,
ACRIN advised participants that up to 50% of those
screened might receive a screen result suspicious for lung
cancer, even though the participants did not have lung
cancer, and that as many as 20% to 50% of those partici-
pants would require additional imaging or other testing to
confirm that findings initially thought to be of concern
were not cancer (Appendix A; see supporting online
information).
Study Enrollment
Demographic information was collected at sites prior to
the T0 screen. Participants at 16 of the 23 ACRIN sites
(Appendix B) were invited to complete HRQoL forms at
baseline and asked to provide contact information. Start-
ing on March 9, 2003, all participants with a positive
screen at these sites, whose results had been received at the
BiostatisticsCenterwithin30daysofthescreeningexami-
nation, who had completed the baseline HRQoL forms,
and who had provided contact information, were
recruited for this study. In the second year of the study, it
became apparent that a substantial number of participants
(6%-10%,dependingon screeningtime point)hadscreen
results “negative for lung cancer, but positive for SIFs.” At
that time, we began to invite participants with SIF screen
results, who met the above criteria, to participate in this
study. Participants were recruited into this study only
once, based on their first eligible screen from the T0, T1,
or T2 screen. We refer to the screen result (T0, T1, T2)
used for accrual as the “index” screen (Fig. 1). For com-
parison, we matched each participant with a positive
screen or a SIF to a negative screen control based on date
of screen, screen type (LDCT, CXR), site of accrual, sex,
and 5-yearagecaliper.
HRQoL and State Anxiety Tools
Global health status was assessed using the Short Form
SF-36 v 2.0 (SF-36),
16,17 a measure of physical and men-
tal function. The SF-36
18-21 has been widely used to eval-
uate the impact of the screening process on healthy
participants, as well as patients with lung cancer.
22 This
Original Article
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easily compared across cancer and noncancer studies.
23,24
The SF-36 is a 36-question health survey. These 36 ques-
tions are used to derive 8 profiles of functional health and
well-being. Physical health is measured by the Physical
Functioning, Role-Physical, Bodily Pain, and General
Health scales. Mental health is described by the Vitality,
Social Functioning, Role-Emotional, and Mental Health
scales. Because it is often easier to report information on
fewer, less detailed parameters, these 8 health dimensions
are used to derive 2 summary measures, a Physical Com-
ponent Score (PCS) and a Mental Component Score
(MCS).
25
The PCS and MCS range from 0 to 100, with a
mean of 50 and a standard deviation of 10. For each of
the SF-36 scale parameters and summary scores, lower
scores indicate lower HRQoL. For adults aged 55-64, the
median norm PCS is 50.65 and MCS is 55.28. For adults
65-74, the median norm PCS is 46.11 and MCS is
56.11.
25 A change of 3 to 5 points in either of the SF-36
component scores across groups or over time is widely
acceptedas aclinicallyimportantchange.
17
State Anxiety was measured using the Spielberger
State Trait Anxiety Inventory (STAI Form Y-1), a 20-
question measure.
26 The STAI has been widely used to
evaluate the impact of the screening process on healthy
community-dwelling participants.
13,18,19 The STAI is a
sensitive indicator of changes in transitory anxiety, such as
might be experienced in a screening program. Scores
range from 20 to 80, with higher scores indicating higher
levels of state anxiety. The median norm for working
adults aged 50 to 69 years is 34.51 for men and 32.20 for
women.
26 A difference between 2 groups with different
exposures of one standard error is generally considered to
represent a small effect, one and one half standard errors
to represent a moderate effect, and two standard errors to
Figure 1. Number of ACRIN NLST participants with data available for analyses of health-related quality of life at each screening
time point.
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27 We chose not to administer the
STAI at baseline to avoid capturing anxiety associated
withthescreeningtest itself.
Administration of HRQoL and Anxiety Tools
For eligible participants meeting the study entry criteria,
the SF-36 and STAI were mailed from the ACRIN Out-
comes and Economics Assessment Unit located at Brown
University to arrive at the participant’s home at approxi-
mately 1 and 6 months after screening. We elected to
measure HRQoL and anxiety after 1 month to assess
short-term effects at a time proximal to the screen, but far
away enough that participants should have received their
results. Per the ACRIN/NLST protocol,
28 participants
were to be informed of their screening results within 4
weeks of the screening test. We measured these indices
again after 6 months to assess the longer-term impact of
the screeningresults.
If questionnaires were not returned, a research asso-
ciate phoned participants at 2 weeks and 1 month to en-
courage completion. We accepted questionnaires up to 15
days past this final scheduled call. Questionnaires received
after thattimewere excludedfrom thestudy.
Statistical Analysis
To distinguish participants with a positive screen who
were free of lung cancer from those participants who did
have lung cancer, and who would potentially benefit from
early diagnosis, we divided screen results into “false pos-
itive,” “true positive,” “SIF,” and “negative.” We defined
“false positives,” using the same definition used for the
main NLST analyses,
2 as screens suspicious for lung can-
cer and free of lung cancer at 1 year, “true positives” as
screens suspicious for lung cancer and diagnosed with
lung cancer within 1 year, “SIFs” as screens with signifi-
cant abnormalities but no evidence of lung cancer, and
“negatives” as screens with no evidence of lung cancer or
SIFs.
We compared enrolled participants (those who met
the entry criteria and were mailed questionnaires) with all
other NLST participants with respect to demographic
characteristics and smoking history using a chi-square test
for categorical data and, due to data departures from nor-
mality,theWilcoxonrank-sumtest forcontinuousdata.
For PCS and MCS, we evaluated whether changes
from the baseline value differed across screen results
(false positive, true positive, SIF, or negative) or study
arm (LDCT, CXR). We used separate models to examine
factors associated with the change from baseline to
1 month and the change from baseline to 6 months, as we
anticipated that the influence of screen result and other
covariates on HRQoL might differ by time point. For
STAI scores,we compareddifferences across screen results
and study arm. As above, we used separate models for
1 and 6 months after screening. Thus, we used 6 separate
regression models (PCS difference from baseline to
1 month and 6 months, MCS difference from baseline to
1 month and 6 months, and STAI at 1 month and
6 months). The time from the baseline questionnaire
completion to the index screen could have been longer
than one year if the index screen was the T1 or T2 screen.
To control for differences occurring in HRQoL between
accrual into the study and the index screen, associated
withchanges in HRQoLindices withincreasing age
29 and
screening experience, we adjusted for the time difference
between the baseline and index screen, as well any abnor-
malscreeningresultsoccurring priortothe indexscreen.
In each of the 6 multivariate models, we included
terms to compare HRQoL indices across screen result and
study arm. In addition, we adjusted for a priori potential
confounders and matching factors, including, the number
of prior screens with a SIF, number of prior screens suspi-
cious for lung cancer, study site, age, sex, education, mari-
tal status, smoking status, race, ethnicity,
29,30 number of
days since the baseline questionnaire had been adminis-
tered, and, for the 1-month models, we assessed whether
the participants knew their screening results at the time of
questionnaire completion. For PCS and MCS models,
the baseline score and the interaction between days since
baselineand baselinescorewerealso included.
ForthePCSandMCS,themodelwasfitusingitera-
tively reweighted least squares (IRLS) regression with a
Huber weight function.
31 The STAI score was modeled as
a count variable (ranging from 20 to 80). There were an
abundance of “20” scores. To adjust for this floor effect
and also account for overdispersion, we used a zero-
inflated (or 0 after subtracting 20 from each score) nega-
tive binomial regression.
32 The Pearson’s chi-squared test
was applied to determine the goodness of fit. The expo-
nentiated regression coefficients from this model estimate
the rate of change in the STAI scores for a oneunit change
ineach independent variable.
RESULTS
A total of 2812 participants met our study entry criteria
and were invited to participate in this study. The index
screen was T0 for 1450 participants, T1 for 923, and T2
for 439 (Fig. 1). HRQoL study participants were similar
with respect to age distribution and smoking status to the
remainder of the NLST population; however, HRQoL
Original Article
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Hispanic, more educated, and unmarried (Table 1). The
HRQoL study sample included fewer participants from
the CXR arm of the study due to lower rates of abnormal-
itiesin thatarm(Table2).
Overall, 1087 participants had screen results suspi-
cious for lung cancer; 1024 were categorized as false-
positive and 63 were true-positive. Of the 63 true-positive
participants, 20 were diagnosed with lung cancer prior to
their 1-month questionnaire, and an additional 21 before
their 6-month questionnaire. A total of 344 participants
were positive for SIFs, and 1381 were screen negative; 227
participants had 1 prior false-positive screen, and 40 had 2;
115 of the 2812 participants had 1 prior SIF, and 6 had 2.
The 383 participants with prior positive or SIF screens
were not eligible for accrual into the study based on those
prior screens, because those screens had either occurred
prior to the start of the study or had not been reported to
theBiostatisticsCenterwithin30 days ofthescreeningtest.
We excluded one participant who was diagnosed with lung
cancerfollowinganegativescreeningexamination.
Response rates were uniformly high, with the lowest
response rates in participants with lung cancer (Table 2).
A total of 2317 participants (82.4%) completed forms
within 45 days of mailing for the 1-month time point,
and 1990 (70.8%) for the 6-month time point. At the
time of completion of the 1-month questionnaire, 2126
(91.8%) knew their screening result. At 6 months, all par-
ticipantsknewtheirscreeningresult.Ofthe2812enrolled
participants, those who were true-positive were more
likely to be in the CXR arm, older, white, and former
smokers. False-positives were more likely to be current
smokers(Supporting Table1).
T h eP C S ,M C S ,a n dt h eS T A Ia r es h o w ni nT a b l e3 .
Mean change in score from baseline and 95% confidence
intervals for the PCS, MCS, and STAI at 1- and 6-month
TABLE 1. Comparison of Baseline Characteristics for Participants Invited to Participate in Quality of Life
Study and the Remaining NLST Participants
Characteristic
HRQoL Study
(N52812)
Non-HRQoL
Study (N550,640)
Total NLST
(N553,452)
N (%) N (%) N (%)
Age at randomization, y
<55 0 (0.0) 5 (0.01) 5 (0.01)
55-59 1162 (41.32) 21,698 (42.85) 22,860 (42.77)
60-64 896 (31.86) 15,473 (30.55) 16,369 (30.62)
65-69 505 (17.96) 9012 (17.80) 9517 (17.80)
70-74 249 (8.85) 4448 (8.78) 4697 (8.79)
75 0 (0.0) 4 (0.01) 4 (0.01)
Sex*
Male 1599 (56.86) 29,931 (59.11) 31,530 (58.99)
Female 1213 (43.14) 20,709 (40.89) 21,922 (41.01)
Race***
White 2649 (94.20) 45,900 (90.64) 48,549 (90.83)
Nonwhite 163 (5.80) 4740 (9.36) 4903 (9.17)
Ethnic group*
Hispanic or Latino 33 (1.17) 902 (1.78) 935 (1.75)
Neither Hispanic or Latino/unknown 2779 (98.83) 49,738 (98.22) 52,517 (98.25)
Smoking status
Former 1478 (52.56) 26,214 (51.77) 27,692 (51.81)
Current 1334 (47.44) 24,426 (48.23) 25,760 (48.19)
Highest level of education completed***
8th grade or less 41 (1.46) 712 (1.41) 753 (1.41)
9th-11th grade 128 (4.55) 2368 (4.68) 2496 (4.67)
High school graduate/GED 598 (21.27) 12,114 (23.92) 12,712 (23.78)
Post–high school training, excluding college 304 (10.81) 7130 (14.08) 7434 (13.91)
Associate’s degree/some college 697 (24.79) 11,580 (22.87) 12,277 (22.97)
Bachelor’s degree 492 (17.50) 8454 (16.69) 8946 (16.74)
Graduate school 475 (16.89) 7125 (14.07) 7600 (14.22)
Other 74 (2.63) 892 (1.76) 966 (1.81)
Unknown 3 (0.11) 265 (0.52) 268 (0.50)
Marital status**
Never married/widowed/separated/divorced 994 (35.35) 16,530 (32.64) 17,524 (32.78)
Married or living as married 1808 (64.30) 33,781 (66.71) 35,589 (66.58)
Data missing 10 (0.36) 329 (0.65) 339 (0.63)
Abbreviations:HRQoL, health-related quality of life; NLST, National Lung Screening Trial.
*P<.05, **P<.01, ***P<.001.
Quality of Life and Anxiety in the NLST/Gareen et al
Cancer November 1, 2014 3405time points are shown in Fig. 2. Detailed information on
the SF-36 subscales is shown in Supporting Table 2 and
Supporting Figure 1. In the crude data, PCS and MCS
showed inconsistent decreases over time (Table 3, Fig. 2),
but these changes disappeared after adjustment for potential
confounders (Table 4). In contrast, decreases in PCS and
MCS evident for the true positive screen group in the crude
data were also evident in the adjusted analyses. We detected
no difference in PCS or MCS by screening arm [LDCT or
CXR](Table 4).
Anxiety was substantially higher among those in the
true-positive group compared with the false positive, SIF,
and negative groups in crude (Table 3) and adjusted (Table
4 )a n a l y s e sa t1a n d6m o n t h sa f t e rs c r e e n i n g .T h e r ew a sn o
difference in state anxietyacross studyarms (Table 4).
DISCUSSION
In this study, drawn from the NLST, the largest random-
ized trial comparing LDCT and CXR, we found no signif-
icant differences in HRQoL (PCS, MCS) or state anxiety
TABLE 2. HRQoL Questionnaire Availability by Study Arm, Index Screen Result, and Time Point
No. of Participants
with Baseline Information
Who Were Invited to
Participate in Study
No. of Participants
who returned the
1-Month Questionnaire
No. of Participants
who returned the
6-Month Questionnaire
N (%) N (%) N (%)
CT Negative 949 (100.0) 801 (84.40) 691 (72.81)
SIFs 268 (100.0) 210 (78.36) 177 (66.04)
False positive 689 (100.0) 583 (84.62) 489 (70.97)
True positive 41 (100.0) 34 (82.93) 29 (70.73)
CXR Negative 432 (100.0) 361 (83.56) 328 (75.93)
SIFs 76 (100.0) 62 (81.58) 49 (64.47)
False positive 335 (100.0) 252 (75.22) 214 (63.88)
True positive 22 (100.0) 14 (63.64) 13 (59.09)
Total 2812 (100.0) 2317 (82.40) 1990 (70.77)
Abbreviations: CT, computed tomography; CXR, chest X-ray; SIF, significant incidental finding.
TABLE 3. Mean (standard deviation)HRQoLand STAIScores by StudyArm,Index ScreenResult, and TimePoint
Baseline (N52812) 1 Month (N52317) 6 Months (N51990)
Mean (SD) Mean (SD) Mean (SD)
CT
SF-36v2: PCS Negative 48.16 (8.97) 47.55 (9.50) 47.89 (9.17)
SIFs 48.38 (9.31) 47.91 (9.44) 47.20 (9.35)
False positive 47.92 (9.98) 47.68 (10.19) 47.08 (10.16)
True positive 46.59 (11.33) 44.50 (11.57) 38.28 (12.57)
SF-36v2: MCS Negative 51.89 (10.19) 51.28 (10.57) 51.36 (10.55)
SIFs 51.52 (9.83) 50.21 (11.88) 51.77 (10.49)
False positive 51.80 (10.04) 50.61 (10.66) 50.42 (11.24)
True positive 52.03 (11.04) 44.14 (14.02) 46.30 (13.65)
STAI Y-1 Negative – 32.67 (11.97) 32.76 (12.36)
SIFs – 33.83 (12.68) 33.19 (12.41)
False positive – 34.34 (12.58) 33.92 (12.77)
True positive – 41.06 (15.10) 37.69 (12.04)
CXR
SF-36v2: PCS Negative 49.23 (8.99) 48.86 (9.61) 48.00 (9.89)
SIFs 48.22 (10.51) 47.55 (10.14) 48.45 (9.55)
False positive 48.64 (9.50) 48.55 (9.52) 47.86 (10.19)
True positive 48.52 (9.88) 42.08 (11.06) 38.48 (10.04)
SF-36v2: MCS Negative 52.74 (9.72) 51.09 (10.99) 51.51 (10.39)
SIFs 50.89 (10.14) 49.98 (10.87) 51.04 (9.18)
False positive 51.99 (9.17) 51.09 (10.35) 51.44 (9.79)
True positive 53.77 (8.57) 51.42 (9.89) 46.22 (12.17)
STAI Y-1 Negative – 32.93 (12.49) 33.09 (11.90)
SIFs – 33.89 (12.05) 33.79 (11.32)
False positive – 32.57 (12.13) 32.61 (11.59)
True positive – 39.43 (11.66) 39.38 (14.47)
Abbreviations: CT, computed tomography; CXR, chest X-ray; MCS, Mental Component Score; PCS, Physical Component Score; SIF, significant incidental
finding.
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screened false-positive, positive for SIFs, or negative, nor
d i dw ef i n dad i f f e r e n c ei nH R Q o Lo rs t a t ea n x i e t yb y
s c r e e n i n ga r m .W ed i d ,h o w e v e r ,f i n ds i g n i f i c a n t l yl o w e r
Figure 2. Mean change in score from baseline and 95% confi-
dence intervals: (A) Physical Component Score (PCS), (B)
Mental Component Score (MCS), and (C) STAI Score by time
point of data collection.
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state anxiety for those who screened true-positive and
developed lung cancer within 1 year of their screening ex-
amination, compared with all other screening groups.
These findings are relevant to the anticipated adop-
tion of LDCT screening in the United States. They pro-
vide evidence that in a large screening program in which
participants received extensive counseling as part of the
consent process, screening was not associated with high
psychological costs for participants who screened positive
but were free of lung cancer. Our findings suggest that
practice guidelines for LDCT screening should include
recommendationsforcounselingregardingthepotentially
high rate of false-positive and SIF screen results in order
tominimizetheimpactofscreeningonHRQoLandanxi-
ety. This is also the first report of the effect of SIF findings
on HRQoLand anxietyfollowinglung screening.
The current findings are consistent with those reported
for a substudy of NLST participants in which we found that
lung cancer worry was low, and lung screening did not
change participants’ riskperceptionsof lungcancer.
33,34
Our findings, that there was no association between
global HRQoL and false-positive screen results, are con-
sistent with those reported by Van den Bergh et al. Their
indeterminate group is comparable to our false positive
group.
12 However, Van den Bergh et al. did report higher
lung-cancer–specific distress among participants with
false-positive (indeterminate) as compared with negative
screen results.
12 We chose to administer global health
measures to allow comparison of the impact of lung
screening with other health interventions and for their
utility for cost-effectiveness analysis. Although lung-
cancer–specific measures are useful to understand health
behaviors associated with lung screening, we did not
administer these tools in the NLST due to concerns
regarding participant burden. Presumably, if the impact
of lung screening on disease-specific HRQoL were severe
enough, it would be reflected in these global measures.
Disease-specific measures, such as lung cancer distress, are
of interest when planning counseling programs; however,
we feel that global measures are more useful for compari-
sons across alternative health interventions or health con-
ditions. We chose to focus on global HRQoL, because
such comparisons are needed to make decisions on the
allocationof healthcareresources.
Wefoundnodifferenceinstateanxietybetweenpar-
ticipants with false positive and negative screen results.
This finding is consistent with results reported from the
NELSON study,
12 but differed from that reported for
participants in the PLuSS study.
13 This discrepancy may
be attributable to differences in the information provided
to participants during the consent process. NLST partici-
pants were advised that as many as 50% of participants
might receive a false-positive screen result requiring addi-
tional imaging, whereas PLuSS participants were advised
of apotential false-positive rate of25%(personal commu-
nication David Wilson MD, October 2012). PLuSS was
also a smaller, single-center study, whereas the NLST was
alarge,multicenterstudywithextendedfollow-up.
Limitations
The NLST false-positive group was heterogeneous with
respect totheir screen findingsand knowledge oftheir lung
cancerstatusatthetimethattheycompletedtheirquestion-
naires. Participants with small nodules with no contrast
enhancement or large masses might receive a definitive di-
agnosis shortly after screening, whereas those with unde-
fined nodules might require monitoring over an extended
period. Thus, some participants learned their lung cancer
status (as opposed to their screening test result) prior to
completing their 1-month questionnaire, some prior to
completing their 6-month questionnaire, and some after
completing both questionnaires. We did nothave informa-
tion on the precise date on which each participant received
their final diagnosis. However, the range of participant ex-
perience that we report here mirrors that to be expected
with the implementation of a community screening pro-
gram, and provides reassurance that NLST screening par-
ticipants understood the cancer screening process,
including the high probability of receiving a false-positive
result and the potential need for continued monitoring to
ensurethebenignnatureofscreenfindings.
Although we enrolled participants at each of the 3
screening examinations (T0, T1, T2) to maximize the
number of participants, each participant entered this
study at a single time point. We adjusted our analyses for
potential differences due to time point and past abnormal
results(false-positiveor SIF)atprior screens.
In addition, our original study design matched par-
ticipants with abnormal results (positive for lung cancer
or SIFs) with negative controls. To avoid dropping partic-
ipants whose match failed to return questionnaires, we
used an unmatched analysis. We adjusted for potential
confounding by including the matching variables in our
multivariate analyses.
35
Conclusions
For participants in a lung cancer screening trial with a
detailed informed consent that provided information
regarding the high risk of a false-positive screen and
Original Article
3408 Cancer November 1, 2014associatedfollow-up,HRQoLandstateanxietydidnotdif-
fer at 1 or 6 months after screening for participants with
false-positive, SIF, or negative screen results. HRQoL was
significantly lower and state anxiety significantly higher for
participantswithtrue-positivescreenresults.
These results provide evidence that in a screening
program that includes counseling and advises participants
of the high likelihood of a false-positive screen and addi-
tional testing, there may be no impact on HRQoL or anx-
ietyforparticipantswhoarefree oflung cancer.
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